THE SUSCEPTIBILITY OF KAPOSI SARCOMA CELLS TO NATURAL KILLER (NK) CELL-MEDIATED CYTOTOXICITY (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


THE SUSCEPTIBILITY OF KAPOSI SARCOMA CELLS TO NATURAL KILLER (NK) CELL-MEDIATED CYTOTOXICITY (MEETING ABSTRACT)

FASEB J; 5(4):A631 1991. Unique Identifier : AIDSLINE ICDB/91676396
Reiter Z; Blatt LM; Taylor MW; Dept. of Biology, Inst. of Molecular Biology, Bloomington, IN; 47405

Abstract: Kaposi's sarcoma (KS) has been found in a high frequency of male AIDS patients. Clinical trials have indicated that interferon (IFN)-alpha is effective in treatment of this tumor. However, it is not known whether the IFN effect is a direct one or is the result of stimulation of a component of the immune system. We have found that KS cells from two different sources were resistant to NK activity. However, KS cells were sensitive to interferon-alpha activated NK cells as measured by 51CR release. This suggests that the clinical effect of interferon is an indirect one involving NK-cell activation. Since the NK-cytolytic process can be divided into discrete stages (recognition between effector cell and target cell, conjugation, effector activation, NK-cytotoxic factor [NKCF] release, and sensitivity to NKCF), we have attempted to identify the process whereby the KS cells are naturally resistant. IFN has a dual effect on NK activity. On the one hand, it increases the cytotoxic activity of NK cells, while on the other, it reduces the susceptibility of the target cells to NK-mediated cytotoxicity. The relationship between IFN, NK activity and KS cell susceptibility are discussed.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Cell Line Cytotoxicity, Immunologic/*IMMUNOLOGY Human Interferon Type I/PHYSIOLOGY Killer Cells, Natural/*IMMUNOLOGY Proteins/PHYSIOLOGY Sarcoma, Kaposi's/*IMMUNOLOGY Tumor Cells, Cultured/*IMMUNOLOGY ABSTRACT

KWDacquiredimmunodeficiencysyndrome/immunologycelllinecytotoxicity,immunologic/KWDimmunologyhumaninterferontypei/physiologykillercells,natural/KWDimmunologyproteins/physiologysarcoma,kaposi's/KWDimmunologytumorcells,cultured/KWDimmunologyabstract
911130
M91B0822

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .